# Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

> **NCT01870726** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM

## Interventions

- **DRUG:** INC280
- **DRUG:** Buparlisib

## Key facts

- **NCT ID:** NCT01870726
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01-09
- **Primary completion:** 2016-12-23
- **Final completion:** 2016-12-23
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2018-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870726, "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01870726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*